Phase II clinical trial - VADS
219885 219885 GALAXIES H&N-202
VADS
Essai clinique fermé
Public cible
Adulte
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
Description de l'essai
It increases the ability of new immunotherapy combinations to prevent or increase tumor progression (anti-tumor activity) by reporting CETEC participant cancer clearance with recurrent/metastatistic PD-L1 positivity.
Liens utiles
CHRISTOPHE LE TOURNEAU
Investigateur principal